Susceptible infections
Neonate: For the treatment of non-CNS infections:
All doses are diluted to a concentration of 1-20 mg/mL given via infusion over 30 minutes. Recommendations may be off-label in some countries (refer to the latest local guidelines).
Gestational Age | Postnatal Age | Dosage |
<32 weeks | <14 days | 20 mg/kg 12 hourly. |
≥14 days | 20 mg/kg 8 hourly. | |
≥32 weeks | <14 days | 20 mg/kg 8 hourly. |
≥14 days | 30 mg/kg 8 hourly. |
Intravenous
Bacterial meningitis
Adult: 2 g 8 hourly via infusion over 15-30 minutes. Treatment duration depends on the patient condition and type of pathogen.
Child: ≥3 months weighing ≤50 kg: 40 mg/kg 8 hourly via infusion over 15-30 minutes; >50 kg: Same as adult dose. Treatment duration depends on the patient condition and type of pathogen.
Child: ≥3 months weighing ≤50 kg: 40 mg/kg 8 hourly via infusion over 15-30 minutes; >50 kg: Same as adult dose. Treatment duration depends on the patient condition and type of pathogen.
Intravenous
Cystic fibrosis
Adult: For bronchopulmonary infections in patients with cystic fibrosis: 2 g 8 hourly via infusion over 15-30 minutes. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months weighing ≤50 kg: 40 mg/kg 8 hourly via infusion over 15-30 minutes; >50 kg: Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months weighing ≤50 kg: 40 mg/kg 8 hourly via infusion over 15-30 minutes; >50 kg: Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Intravenous
Complicated skin and skin structure infections, Complicated urinary tract infections, Gynaecological infections, Lower respiratory tract infections, Septicaemia
Adult: 0.5-1 g 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes. Dosage and treatment duration depend on the type and severity of infection, patient condition, and susceptibility of the pathogen. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months weighing ≤50 kg: 10-20 mg/kg 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes; >50 kg: Same as adult dose. Dosage and treatment duration depend on the type and severity of infection, patient condition, and susceptibility of the pathogen. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months weighing ≤50 kg: 10-20 mg/kg 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes; >50 kg: Same as adult dose. Dosage and treatment duration depend on the type and severity of infection, patient condition, and susceptibility of the pathogen. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Intravenous
Complicated intra-abdominal infections
Adult: 0.5-1 g 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes.
Child: 1-<3 months Gestational age <32 weeks 20 mg/kg 8 hourly via infusion over 30 minutes; Gestational age ≥32 weeks 30 mg/kg 8 hourly via infusion over 30 minutes. ≥3 months weighing ≤50 kg: 10-20 mg/kg 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes; >50 kg: Same as adult dose.
Neonate:
All doses are diluted to a concentration of 1-20 mg/mL given via infusion over 30 minutes.
Child: 1-<3 months Gestational age <32 weeks 20 mg/kg 8 hourly via infusion over 30 minutes; Gestational age ≥32 weeks 30 mg/kg 8 hourly via infusion over 30 minutes. ≥3 months weighing ≤50 kg: 10-20 mg/kg 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes; >50 kg: Same as adult dose.
Neonate:
Gestational Age | Postnatal Age | Dosage |
<32 weeks | <14 days | 20 mg/kg 12 hourly. |
≥14 days | 20 mg/kg 8 hourly. | |
≥32 weeks | <14 days | 20 mg/kg 8 hourly. |
≥14 days | 30 mg/kg 8 hourly. |
Intravenous
Anthrax
Neonate: As part of an appropriate combination regimen for systemic anthrax excluding meningitis:
As part of an appropriate combination regimen in cases where meningitis or disseminated infection in which meningitis cannot be excluded:
All doses are diluted to a concentration of 1-20 mg/mL given via infusion over 30 minutes. Treatment duration: 2-3 weeks or until clinical criteria for improvement are met (whichever is longer). Recommendations may be off-label in some countries (refer to the latest local guidelines).
Gestational Age | Postnatal Age | Dosage |
32-<34 weeks | <1 week | 13.3 mg/kg 8 hourly. |
≥1 week | 20 mg/kg 8 hourly. | |
≥34 weeks | <1 week | 20 mg/kg 8 hourly. |
≥1 week | 20 mg/kg 8 hourly. |
As part of an appropriate combination regimen in cases where meningitis or disseminated infection in which meningitis cannot be excluded:
Gestational Age | Postnatal Age | Dosage |
≥32 weeks | <1 week | 20 mg/kg 8 hourly. |
≥1 week | 30 mg/kg 8 hourly. |
Intravenous
Febrile neutropenia
Adult: As monotherapy or in combination with other anti-infectives: 1 g 8 hourly via infusion over 15-30 minutes or via bolus inj over 3-5 minutes. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months weighing ≤50 kg: 20 mg/kg 8 hourly via infusion over approx 15-30 minutes or via bolus inj over 3-5 minutes; >50 kg: Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months weighing ≤50 kg: 20 mg/kg 8 hourly via infusion over approx 15-30 minutes or via bolus inj over 3-5 minutes; >50 kg: Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).